HealthQuill disease progression
Pfizer Inc. announced that USFDA has accepted its biologics license application for treating bleeding disorders in adults through gene therapy.
Health Research

Gene therapy slows Huntington’s Disease progression by 75%

HQ Team September 25, 2025: Scientists in the United Kingdom have found a novel gene therapy known as AMT-130 that has slowed the.

Read More
British-Swedish AstraZeneca Plc.’s investigational pill to treat an advanced breast cancer has reduced the chance of worsening the disease or the patient dying by 56% compared to the usual treatment.
Drugs Health Pharma

AstraZeneca’s pill to treat breast cancer cuts disease worsening by 56%

HQ Team June 4, 2025: British-Swedish AstraZeneca Plc.’s investigational pill to treat an advanced breast cancer has reduced the chance of worsening the.

Read More
A third of patients with a type of blood cancer, especially those whose disease had returned or not responded to other treatments, have shown “promising” results in an early Johnson & Johnson trial.
Drugs Health Pharma

A third of blood cancer cases in J&J trials live without detectable cancer 

HQ Team June 4, 2025: A third of patients with a type of blood cancer, especially those whose disease had returned or not.

Read More
Definitive evidence has emerged from a global colon cancer trial that people who follow a structured exercise programme after surgery and chemotherapy have better odds of survival and lower risk of cancer coming back.
Drugs Health Research

Exercise helps colon cancer patients live longer, lowers recurrence rate

HQ Team June 3, 2025: Definitive evidence has emerged from a global colon cancer trial that people who follow a structured exercise programme.

Read More
AstraZeneca and Daiichi Sankyo’s breast cancer drug, Enhertu, has cut the risk of disease progression or death by 44% compared to a taxane, trastuzumab and pertuzumab combination. 
Drugs Health Pharma

AstraZeneca, Daiichi’s Enhertu cuts breast cancer progression by 44%

HQ Team June 3, 2025: AstraZeneca and Daiichi Sankyo’s breast cancer drug, Enhertu, has cut the risk of disease progression or death by.

Read More
Merck & Co., Inc.’s drug Keytruda, along with Gilead Sciences Inc.'s antibody-drug conjugate, cut the risk of an aggressive breast cancer advancement and death by 35% during an end-stage trial.
Drugs Health Pharma

Merck, Gilead’s drug for breast cancer cuts progression risk by 35 per cent

HQ Team June 1, 2025: Merck & Co., Inc.’s drug Keytruda, along with Gilead Sciences Inc.’s antibody-drug conjugate, cut the risk of an.

Read More
An investigational oral breast cancer drug being developed by Pfizer and Arvinas Inc. has been shown to delay progression of the disease by three months compared to AstraZeneca’s Faslodex or fulvestrant.
Drugs Health Pharma

Pfizer, Arvinas’ breast cancer test drug scores on disease advance

HQ Team June 1, 2025: An investigational oral breast cancer drug being developed by Pfizer and Arvinas Inc. has been shown to delay.

Read More
Sanofi SA will acquire Vigil Neuroscience, Inc., a publicly traded clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases, for $470 million.
Drugs Health Pharma

France’s Sanofi SA to acquire US-based Vigil Neuroscience for $470 million 

HQ Team May 22, 2025: Sanofi SA will acquire Vigil Neuroscience, Inc., a publicly traded clinical-stage biotechnology company focused on developing novel therapies.

Read More
Daiichi Sankyo and Merck & Co., Inc. will initiate talks with global regulatory agencies after an end-stage trial of its drug for a form of lung cancer improved patients’ chances of extending survival without the disease progressing.
Drugs Health Pharma

Daiichi Sankyo-Merck’s trial lung cancer drug meets primary goal

Daiichi Sankyo and Merck & Co., Inc. will initiate talks with global regulatory agencies after an end-stage trial of its drug for a.

Read More
Switzerland’s Novartis AG has received accelerated approval from the USFDA for its drug to reduce elevated levels of proteins in the urine of patients with a rare type of kidney disease.
Drugs Health Pharma

Novartis’s drug to treat rare kidney disease gets USFDA approval 

Switzerland’s Novartis AG has received accelerated approval from the USFDA for its drug to reduce elevated levels of proteins in the urine of.

Read More